• Home
  • About Nanexa
    • Company
    • Management
    • Board
    • Our story
  • Pharmashell®
  • Projects
  • Investors
    • Financial reports
    • Press releases
    • Corporate governance
    • The Stock
    • Analytiker
    • Calendar
  • Media
    • Pressreleases
    • Subscribe
    • Publications
    • Presentations
  • Contact
  • English
    • Swedish

Investors

  • Financial reports
  • Pressreleases
  • Corporate governance
    • Shareholders’ meeting
    • Nomination commitee
    • Board
    • Management
    • Auditor
    • Articles of association
  • The Stock
    • Ownership Structure
  • Analytiker
  • Calendar

Analytiker

Analysts who follow Nanexa:

Fredrik Thor, Redeye
fredrik.thor@redeye.se
https://www.redeye.se/company/nanexa/updates

Adam Karlsson, ABG Sundal Collier
adam.karlsson@abgsc.se
https://cr.abgsc.com/foretag/nanexa/Equity-research/

John Widmark, Emergers
johan@emergers.se
https://www.emergers.se/bolag_nanexa/

Investors

  • Financial reports
  • Pressreleases
  • Corporate governance
    • Shareholders’ meeting
    • Nomination commitee
    • Board
    • Management
    • Auditor
    • Articles of association
  • The Stock
    • Ownership Structure
  • Analytiker
  • Calendar

Nanexa is a pharmaceutical company developing injectable drug products based on the proprietary and innovative drug delivery system PharmaShell® – the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. Nanexa develops its own products and also has collaboration agreements with several pharma companies, among others AstraZeneca.

CONTACT

Nanexa AB, Virdings Allé 2, SE-75450 Uppsala, Sweden
Phone: +46 (0) 18 100 300
E-mail: info@nanexa.se
Org nr. 556833-0285

Integritetspolicy
Integritetspolicy för aktieägare

  • English
  • Svenska